3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
NIH
1
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Neoplasms
4
Febrile Neutropenia
3
Urinary Bladder Neoplasms
2
Myelodysplastic Syndromes
2
Leukemia, Myeloid, Acute
2
Urinary Tract Infections
1
Stem Cell Transplant Complications
1
Sepsis
1
Prostatic Neoplasms
1
Prostatic Hyperplasia
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Neutropenia
1
Myeloproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Emergencies
1
Interventions
Filgrastim
7
pegylated granulocyte colony-stimulating factor
5
pegfilgrastim
5
Cytarabine
4
Ciprofloxacin
4
Cefepime
4
Vancomycin
3
Leucovorin
3
Fluorouracil
3
Amikacin
3
trifluridine tipiracil drug combination
2
Piperacillin, Tazobactam Drug Combination
2
Methylprednisolone
2
Meropenem
2
Irinotecan
2
Etoposide
2
Daptomycin
2
Cisplatin
2
Ceftazidime
2
ziprasidone
1
trilaciclib
1
sargramostim
1
niraparib
1
liposomal amphotericin B
1
lintuzumab
1
leridistim
1
isavuconazole
1
fludarabine phosphate
1
flt3 ligand protein
1
fish oil triglycerides
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Neutropenia
×
Levofloxacin
×
Clear all
NCT07528417
2026-04-22
MYELO-CAN:ABX
University of Manitoba
Phase 2
Not yet recruiting
75 enrolled